Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus plus metronomic oral cyclophosphamide in metastatic renal cell cancer
NL-OMON21801Phase 2Recruiting
- Sponsor
- VU University Medical Center
- Start
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of everolimus and cyclophosphamide in renal cell carcinoma (RCC) (9 arms), sponsored by VU University Medical Center. Primary endpoints: Recommended cyclophosphamide dose and schedule, Safety and tolerability and 1 more. Started Oct 2011; status: recruiting.
02
Drugs
everolimuscyclophosphamide
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NL-OMON21801.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21801.